Author(s): Anny Setijo Rahaju, Alphania Rahniayu, Etty Hary Kusumastuti, Priangga Adi Wiratama, Pamela Kusumadewi P. Thaib, Mimi Takaria

Email(s): anny_sr@fk.unair.ac.id

DOI: 10.52711/0974-360X.2024.00017   

Address: Anny Setijo Rahaju1,2,3*, Alphania Rahniayu1,2,3, Etty Hary Kusumastuti1,2, Priangga Adi Wiratama1,2, Pamela Kusumadewi P. Thaib1,2, Mimi Takaria1,2
1Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
2Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
3Universitas Airlangga Teaching Hospital, Surabaya, Indonesia.
*Corresponding Author

Published In:   Volume - 17,      Issue - 1,     Year - 2024


ABSTRACT:
Renal cell carcinoma (RCC) is a malignant neoplasm originating from renal epithelium, with the clear cell renal cell carcinoma (ccRCC)being the most common type (80%) and the most common cause of death among other types of kidney cancer. Pathological stage is an important parameter that affects ccRCC survival, followed by nuclear grade. Pathological staging of RCC according to the AJCC (American Joint Committee on Cancer) TNM system 8th edition is based on local extension of the main tumor (T), involvement of lymph node (N), and metastasis (M). Ki-67 is a marker of proliferation used to assess tumor grade. High Ki-67 correlates with poor prognosis, advanced clinical and pathological features, thus Ki-67 can be used as a biomarker in the management of RCC.Ki-67 is routinely used to see the proliferation index in various cases of malignancy, but not in kidney malignancy. Programmed death ligand 1 (PD-L1) acts as a negative regulator of T cell-mediated anti-tumor immune responses. PD-L1 is expressed on T cells, B cells, macrophages, dendritic cells, endothelial cells and in various tumor cells including ccRCC. This study aims to determine the correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Material and Method: This was an observational analytical study with cross-sectional approach toward 52 cases of ccRCC whose diagnosis was made histopathologically at the Anatomical Pathology Installation of Dr. Soetomo General Academic Hospital Surabaya from January 2014 to December 2020. Immunohistochemical stainingwas carried out using Ki-67 and PD-L1 antibodies, followed by an assessment using a scoring system. T-stage data were obtained from the patients’ medical recordswhich were then analyzed statistically with the Spearman test. Result: The study included 52 cases of ccRCC obtained from nephrectomy specimens at RSUD dr. Soetomo between 2014–2020. The age distribution of the subjects was 29–69 years and the mean and median age was 53 years. The ratio of male patients compared to female patients was 2.5:1. The majority was stage T2 (50%). Statistical test results showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas (p=0.965 and p=0.680). Conclusion: This study showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Nonetheless PD-L1 can be considered as an important biomarker with a poorer prognosis and aggressive clinicopathological findings in patients with RCC.


Cite this article:
Anny Setijo Rahaju, Alphania Rahniayu, Etty Hary Kusumastuti, Priangga Adi Wiratama, Pamela Kusumadewi P. Thaib, Mimi Takaria. Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas. Research Journal of Pharmacy and Technology. 2024; 17(1):109-4. doi: 10.52711/0974-360X.2024.00017

Cite(Electronic):
Anny Setijo Rahaju, Alphania Rahniayu, Etty Hary Kusumastuti, Priangga Adi Wiratama, Pamela Kusumadewi P. Thaib, Mimi Takaria. Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas. Research Journal of Pharmacy and Technology. 2024; 17(1):109-4. doi: 10.52711/0974-360X.2024.00017   Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-1-17


REFERENCES:
1.    Lee BH. Commentary on: An integrated metabolic atlas of clear cell renal cell carcinoma. Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, Chen Y, Stirdivant SM, Russo P, Chen YB, Tickoo SK, Reuter VE, Cheng EH, Sander C, Hsieh JJ. Urol Oncol Semin Orig Investig. 2017; 35(9): 579–80. doi: 10.1016/j.urolonc.2017.07.023.
2.    Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3: 17009. doi: 10.1038/nrdp.2017.9.
3.    Hota BM, Naaz N, Pujitha M, Banoth SB, Basavaih PGC. Recurrent Peri-Op Haematuria in repeat lower segment caesarean section: an unusual Presentation of Renal Cell Carcinoma in Pregnancy (A Case report with Literature Review). Bali Med J. 2015; 4(2): 44-8.
4.    Erdoğan F, Demirel A, Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract. 2004; 58(4):333-6. doi: 10.1111/j.1368-5031.2004.00008.x.
5.    Taneja K, Williamson SR. Updates in Pathologic Staging and Histologic Grading of Renal Cell Carcinoma. Surg Pathol Clin. 2018; 11(4): 797-812. doi: 10.1016/j.path.2018.07.004.
6.    Abouassaly R, Campbell SC. Kidney cancer. Geriatric Urology. 2013. 309–323.
7.    Tatli Dogan H, Kiran M, Bilgin B, Kiliçarslan A, Sendur MAN, Yalçin B, Ardiçoglu A, Atmaca AF, Gumuskaya B. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression. Diagn Pathol. 2018; 13(1): 60. doi: 10.1186/s13000-018-0742-8.
8.    Carlsson J, Sundqvist P, Kosuta V, Fält A, Giunchi F, Fiorentino M, Davidsson S. PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma. Appl Immunohistochem Mol Morphol. 2020; 28(3): 213-220. doi: 10.1097/PAI.0000000000000766.
9.    Fatimah S, Rahaju AS, Rahniayu A. Role of Claudin-4 and Matrix Metalloproteinase-2 in Tumor Invasion of Colorectal Adenocarcinoma. Research Journal of Pharmacy and Technology. 2021; 14(9): 4795-0. doi: 10.52711/0974-360X.2021.00834.
10.    Grimm MO, Leucht K, Grünwald V, Foller S. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. J Clin Med. 2020; 9(2): 565. doi: 10.3390/jcm9020565.
11.    Kammerer-Jacquet SF, Deleuze A, Saout J, Mathieu R, Laguerre B, Verhoest G, Dugay F, Belaud-Rotureau MA, Bensalah K, Rioux-Leclercq N. Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. Int J Mol Sci. 2019; 20(7): 1692. doi: 10.3390/ijms20071692.
12.    Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. 2016; 139(2): 396-403. doi: 10.1002/ijc.30077.
13.    Deepak H B, Sabina Evan Prince. A Systematic Review on the Role of PD-1 and its Ligands in Autoimmunity. Research J. Pharm. and Tech. 2017; 10(8): 2771-2776. doi: 10.5958/0974-360X.2017.00491.7.
14.    Zhu Q, Cai MY, Weng DS, Zhao JJ, Pan QZ, Wang QJ, Tang Y, He J, Li M, Xia JC. PD-L1 expression patterns in tumour cells and their association with CD8+ tumour infiltrating lymphocytes in clear cell renal cell carcinoma. J Cancer. 2019; 10(5): 1154-1161. doi: 10.7150/jca.29052.
15.    Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019; 491: 39-45. doi: 10.1016/j.cca.2019.01.011.
16.    Murti K, Warli SM, Laksmi LI. Relations between KI-67 immunohistochemistry expression with histopathology grading and prostate-specific antigen (PSA) values in adenocarcinoma prostate at Dr H. Adam Malik Hospital, Medan Indonesia. Bali Med J. 2017; 6(2): 289-93.
17.    Xie Y, Chen L, Ma X, Li H, Gu L, Gao Y, Fan Y, Zhang Y, Zhang X. Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis. Sci Rep. 2017; 7: 44281. doi: 10.1038/srep44281.
18.    Dewi IGASM, Susraini AAAN, Ekawati NP. HER2/neu and Ki-67 as prognostic factors in serous type ovarian carcinoma. Bali Med J. 2020; 9(2): 567-71.
19.    Miranti IP, Istiadi H, Larasati PAA, Wijaya I, Puspasari D, Karlowee V. Prostate acinar adenocarcinoma: a comparative study of Her-2 and Ki-67 expression on Gleason patterns. Bali Med J.  2021; 10(2): 677-82.
20.    Mahasin SZ, Aloudah N, Al-Surimi K, Alkhateeb SS. Epidemiology profile of renal cell carcinoma: A 10-year patients' experience at King Abdulaziz Medical City, National Guard Health Affairs, Saudi Arabia. Urol Ann. 2018; 10(1): 59-64. doi: 10.4103/UA.UA_102_17.
21.    Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, Rawla P, Barsouk A. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020; 11(3): 79-87. doi: 10.14740/wjon1279.
22.    Ghartimagar D, Shrestha MK, Ghosh A, Ruwanpathirana RE, Regmi S. Renal cell carcinoma with widespread metastasis in 19 years old young male - A rare case report. Int J Surg Case Rep. 2021; 86: 106345. doi: 10.1016/j.ijscr.2021.106345.
23.    Li X, Xu Z, Xu T, Qi F, Song N. Basic Characteristics and Survival Outcomes of Asian-American Patients with Clear Cell Renal Cell Carcinoma and Comparisons with White Patients: A Population-Based Analysis. Int J Gen Med. 2021; 14: 7869-7883. doi: 10.2147/IJGM.S340284.
24.    Globocan. Globocan 2020: New Global Cancer Data. 2020;1–2.
25.    Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022; 39(3).
26.    Res M, Ruts C, Hospital CR, Sciences M, Committee IE, Crh-smims S. Prevalence of. 2018;517–20.
27.    Delahunt B, Eble JN, Egevad L, Samaratunga H. Grading of renal cell carcinoma. Histopathology. 2019; 74(1): 4-17. doi: 10.1111/his.13735.
28.    Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR; Members of the ISUP Renal Tumor Panel. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013; 37(10): 1490-504. doi: 10.1097/PAS.0b013e318299f0fb.
29.    Ferdous AJ, Hamzah SK. SOX17 and RASSAF1A Promoters Methylation in Circulation Tumor Cell and Cell Free DNA Isolated from Plasma in Breast Cancer Iraqi Women Patients. Research J. Pharm. and Tech 2018; 11(5): 2000-2005. doi: 10.5958/0974-360X.2018.00372.4.
30.    Wang X, Teng F, Kong L, Yu J. PD-L1 Expression in Human Cancers and Its Association With Clinical Outcomes. Onco Targets Ther. 2016; 9: 5023-39. doi: 10.2147/OTT.S105862.
31.    Thaib PKP, Rahaju AS. Clinicopathological Profile of Clear Cell Renal Cell Carcinoma. Int J Heal Med Sci. 2022; 5(1): 91–100. doi:10.21744/ijhms.v5n1.1846.
32.    Tiwari P, Kumar L, Singh G, Seth A, Thulkar S. Renal cell cancer: Clinicopathological Profile and Survival Outcomes. Indian J Med Paediatr Oncol. 2018; 39(1): 23–7. doi: 10.4103/ijmpo.ijmpo_126_16.
33.    Gudbjartsson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur Urol. 2005; 48(4): 593-600. doi: 10.1016/j.eururo.2005.04.016.
34.    Thaib PKP, Rahaju AS, Kusumastuti EH.Correlation between CXCR4 and MMP-2 Expression with T Stage in Clear Cell Renal Cell Carcinoma. Research Journal of Pharmacy and Technology. 2023; 16(2): 821-9. doi: 10.52711/0974-360X.2023.00140
35.    Larrinaga G, Solano-Iturri JD, Errarte P, Unda M, Loizaga-Iriarte A, Pérez-Fernández A, Echevarría E, Asumendi A, Manini C, Angulo JC, López JI. Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021; 13(4): 667. doi: 10.3390/cancers13040667.
36.    Vijayabaskaran M, Babu G, Venkateswaramurthy N, Sivakumar P, Perumal P, Sivakumar T, Sambathkumar R, Jayakar B. Antitumor Activity and Antioxidant Role of Ethanolic Extract of Pseudarthria viscida Linn against Ehrlich Ascites Carcinoma. Asian J. Research Chem. 2011; 4(1): 110-113.
37.    El-Sharkawy K, El-Brrati MMA, Ghardaly IA, Ali M. Design and synthesis of thiazol derivatives with biological evaluations as antitumor agents. Research J. Pharm. and Tech. 2015; 8(5): 520-528. doi: 10.5958/0974-360X.2015.00087.6.
38.    Noviyani R, Suwiyoga K, Lesmana I, Niruri R, Tunas K, Budiana and ING. Differences Of Tumor Masses And Hemoglobin Levels In Cervical Cancer Squamous Cell Type Patients Treated With Combination Of Paclitaxel And Carboplatin Chemotherapy. Bali Med J. 2014; 3(1): 15-7.
39.    Fadholly A, Ansori ANM, Utomo B. Anticancer Effect of Naringin on Human Colon Cancer (WiDr Cells): In Vitro Study. Research Journal of Pharmacy and Technology. 2022; 15(2): 885-888. DOI: 10.52711/0974-360X.2022.00148.
40.    Avinash BT, Pawan NK, Priyanka SC, Nareshkumar RJ. Nanotechnology: The Future of Cancer. Asian J. Pharm. Tech. 2019; 9(1): 40-48. doi: 10.5958/2231-5713.2019.00008.4.
41.    Raj KP, Kavita RL. Anticancer Potential of Coumarin derivatives: A Review. Asian Journal of Pharmacy and Technology. 2022; 12(4): 391-0. doi: 10.52711/2231-5713.2022.00060.
42.    Pujitha S, Jaswanth A, Ganesh A, Begum I, Jahan N. Evaluation of Anticancer activity of Maytenus emarginata on Ehrlich’s Ascites Carcinoma treated mice. Asian J. Res. Pharm. Sci. 2018; 8(3): 133-136. doi: 10.5958/2231-5659.2018.00023.1.
43.    Kumar S, Koul S, Meena AK, Saxena AK, Suri OP, Dhar KL. Synthesis and Antitumor Activity of Combretastatin Analogues. Asian J. Research Chem. 2011; 4(6): 902-904.
44.    Bailly C, Thuru X, Quesnel B. Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases. Cancers (Basel). 2021; 13(12): 3034. doi: 10.3390/cancers13123034.
45.    Leite KR, Reis ST, Junior JP, Zerati M, Gomes Dde O, Camara-Lopes LH, Srougi M. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol. 2015; 10: 189. doi: 10.1186/s13000-015-0414-x.
46.    Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, Chung JH, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018; 13(9): 1302-1311. doi: 10.1016/j.jtho.2018.05.013.
47.    Krigsfeld GS, Prince EA, Pratt J, Chizhevsky V, William Ragheb J, Novotny J Jr, Huron D. Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types. J Clin Pathol. 2020; 73(10): 656-664. doi: 10.1136/jclinpath-2020-206466.
48.    Xie Y, Chen L, Ma X, Li H, Gu L, Gao Y, Fan Y, Zhang Y, Zhang X. Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis. Sci Rep. 2017; 7: 44281. doi: 10.1038/srep44281.
49.    Carretero-González A, Lora D, Martín Sobrino I, Sáez Sanz I, Bourlon MT, AnidoHerranz U, Martínez Chanzá N, Castellano D, de Velasco G. The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials. Cancers (Basel). 2020; 12(7): 1945. doi: 10.3390/cancers12071945.
50.    Elkhodary HS, Nasr KE, Ahmed SH, Shakweer MM, Ezz-eldin MMA. Clinicopathological Correlation And Prognostic Value ofPD-L1 Expression in Renal Cell Carcinoma. Immunopathol Persa. 2022; 8(2): e30329. doi: 10.34172/ ipp.2022.30329.
51.    Tabriz HM, Nazar E, Akhlaghi N, Javadi AE. Expression of Programmed Death-1 Ligand in Renal Cell Carcinoma and Its Relationship with Pathologic Findings and Disease-Free Survival. Nephro-Urol Mon. 2022; 14(4): e127476. doi: 10.5812/numonthly-127476.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available